Evidence mapPaperPMID 39692857Full record

ReviewArchives of toxicology2025

Immunology and treatments of fatty liver disease.

Sainan Tang, Shanshan Wu, Wenzhe Zhang, Lili Ma, Li Zuo, Hua Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Archives of toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sainan TangInnovation and Entrepreneurship Laboratory for College Students, Anhui Medical University, Hefei, Anhui, China.
Shanshan WuInnovation and Entrepreneurship Laboratory for College Students, Anhui Medical University, Hefei, Anhui, China.
Wenzhe ZhangInnovation and Entrepreneurship Laboratory for College Students, Anhui Medical University, Hefei, Anhui, China.
Lili MaInnovation and Entrepreneurship Laboratory for College Students, Anhui Medical University, Hefei, Anhui, China.
Li ZuoInnovation and Entrepreneurship Laboratory for College Students, Anhui Medical University, Hefei, Anhui, China. lizuo1981@163.com.
Hua WangDepartment of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. wanghua@ahmu.edu.cn.ORCID 0000-0002-2605-5697

Funding

National Natural Science Foundation of China 82070548National Natural Science Foundation of China 822250008National Natural Science Foundation of China 82270589Natural Science Foundation of Science and Technology Department of Anhui Province 2308085J28
6 · The paper itself

Abstract

Alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) are two major chronic liver diseases worldwide. The triggers for fatty liver can be derived from external sources such as adipose tissue, the gut, personal diet, and genetics, or internal sources, including immune cell responses, lipotoxicity, hepatocyte death, mitochondrial dysfunction, and extracellular vesicles. However, their pathogenesis varies to some extent. This review summarizes various immune mechanisms and therapeutic targets associated with these two types of fatty liver disease. It describes the gut-liver axis and adipose tissue-liver crosstalk, as well as the roles of different immune cells (both innate and adaptive immune cells) in fatty liver disease. Additionally, mitochondrial dysfunction, extracellular vesicles, microRNAs (miRNAs), and gastrointestinal hormones are also related to the pathogenesis of fatty liver. Understanding the pathogenesis of fatty liver and corresponding therapeutic strategies provides a new perspective for developing novel treatments for fatty liver disease.

Indexed as

Fatty Liver, AlcoholicNon-alcoholic Fatty Liver DiseaseAdipose TissueAnimalsHumansImmunity, InnateLiverMicroRNAsMicroRNAsALDImmuneInflammationNAFLDTreatment

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.